[Dynamic changes of the platelet granule membrane glycoprotein level in patients with acute myocardial infarction before and after thrombolysis].
Platelet granule membrane glycoprotein (GMP-140) level was measured by using 125I labelled monoclonal antibody in 37 patients with acute myocardial infarction before and after thrombolytic therapy. In a nonthrombolysis group, it was shown that platelet GMP-140 increased significantly at the moment of admission and reached peak value 48 hours after AMI attack, then it decreased gradually and returned to baseline on the fifth day. In the thrombolysis group, with the patency of infarct related arteries, it dropped quickly (1-6 hours) after thrombolytic therapy; if the infarct related arteries were not patent, platelet GMP-140 increased rapidly after thrombolytic therapy and reached the highest at 6 hours, then it returned to baseline on the third day. It is suggested that the changes of platelet function could play an important role in thrombus formation and lysis; the rapid decrease of the number of GMP-140 molecules on platelet surface might be a new index for the pateacy of infarct related arteries.
Lu
J
J
Ruijin Hospital, Shanghai Second Medical University.
Qi
W
W
Shao
H
H
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D019007:P-Selectin / Q000097:blood*; D010960:Plasminogen Activators / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D019007:P-Selectin; D013300:Streptokinase; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator